BioCryst Pharmaceuticals Inc. (BCRX)

3.39
NASDAQ : Health Technology
Prev Close 3.48
Day Low/High 3.37 / 3.49
52 Wk Low/High 2.80 / 9.95
Avg Volume 2.03M
Exchange NASDAQ
Shares Outstanding 110.31M
Market Cap 383.89M
EPS -1.00
P/E Ratio N/A
Div & Yield N.A. (N.A)
Your Vote Counts: Who Is the Worst Biotech CEO of 2012?

Your Vote Counts: Who Is the Worst Biotech CEO of 2012?

Readers get to decide which of the CEOs from BioSante, BioCryst, Peregrine or Cell Therapeutics deserve the dishonor.

BioCryst Pharmaceuticals And Presidio Pharmaceuticals Mutually Terminate Merger Transaction

BioCryst Pharmaceuticals And Presidio Pharmaceuticals Mutually Terminate Merger Transaction

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) and privately held Presidio Pharmaceuticals, Inc.

5 Biotech Stocks Rising on Unusual Volume

5 Biotech Stocks Rising on Unusual Volume

Here are several biotech and pharma stocks under $10 that are making large moves to the upside today.

BioCryst Broad-Spectrum Antiviral BCX4430 Highly Effective Against Yellow Fever In A Preclinical Disease Model

BioCryst Broad-Spectrum Antiviral BCX4430 Highly Effective Against Yellow Fever In A Preclinical Disease Model

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced proof-of-principle data demonstrating that BCX4430 is efficacious and well tolerated in a preclinical disease model for evaluating efficacy against...

BioCryst Provides Corporate Update And Reports Third Quarter 2012 Financial Results

BioCryst Provides Corporate Update And Reports Third Quarter 2012 Financial Results

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced financial results for the third quarter and nine months ended September 30, 2012.

BioCryst Announces Outcome From The Peramivir Phase 3 Interim Analysis

BioCryst Announces Outcome From The Peramivir Phase 3 Interim Analysis

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced completion of the planned interim analysis of the peramivir Phase 3 trial in patients admitted to the hospital with serious influenza.

BioCryst To Report Third Quarter 2012 Financial Results On November 8, 2012

BioCryst To Report Third Quarter 2012 Financial Results On November 8, 2012

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that its third quarter 2012 financial results will be released on Thursday, November 8, 2012.

BioCryst Provides Update Regarding BCX5191 Development Plan Following Discussion With FDA

BioCryst Provides Update Regarding BCX5191 Development Plan Following Discussion With FDA

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced the withdrawal of its Investigational New Drug application (IND) for the antiviral nucleoside, BCX5191, following a discussion with the U.

BioCryst Pharmaceuticals And Presidio Pharmaceuticals To Merge

BioCryst Pharmaceuticals And Presidio Pharmaceuticals To Merge

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) and privately held Presidio Pharmaceuticals, Inc.

BioCryst Provides Corporate Update And Reports Second Quarter 2012 Financial Results

BioCryst Provides Corporate Update And Reports Second Quarter 2012 Financial Results

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced financial results for the second quarter and six months ended June 30, 2012.

Buy or Get Out of the Way

Market players are adding long exposure as the market runs away from them.

Biotech Stock Mailbag: Amarin, Sarepta

Biotech Stock Mailbag: Amarin, Sarepta

Biotech columnist Adam Feuerstein answers readers' questions about health-care companies.

BioCryst Announces Positive Results From Two Ulodesine Phase 2 Trials In Patients With Gout

BioCryst Announces Positive Results From Two Ulodesine Phase 2 Trials In Patients With Gout

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced favorable 52-week safety results and sustained efficacy from the extension phase of its randomized Phase 2b trial of ulodesine (BCX4208)...

BioCryst To Report Second Quarter 2012 Financial Results On August 2, 2012

BioCryst To Report Second Quarter 2012 Financial Results On August 2, 2012

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that its second quarter 2012 financial results will be released on Thursday, August 2, 2012.

BioCryst To Present At The 7th Annual JMP Securities Healthcare Conference

BioCryst To Present At The 7th Annual JMP Securities Healthcare Conference

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that Dr.

4 Stocks Poised to Break Out

4 Stocks Poised to Break Out

The LiveDeal breakout we mentioned yesterday has happened today! Trading stocks that trigger major breakouts can lead to massive profits.

BioCryst Presents Results From Its BCX4208 Gout Program At The Annual European Congress Of Rheumatology

BioCryst Presents Results From Its BCX4208 Gout Program At The Annual European Congress Of Rheumatology

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that additional safety and efficacy results from its BCX4208 gout program will be presented at the Annual European Congress of Rheumatology hosted...

BioCryst To Present At Two Upcoming Investor Conferences

BioCryst To Present At Two Upcoming Investor Conferences

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that executives from BioCryst are scheduled to present and provide a corporate summary and update regarding the Company’s clinical programs at the ...

Hot Biotech Stocks Traded by Hedge Funds in First Quarter

Hot Biotech Stocks Traded by Hedge Funds in First Quarter

A closer look at 13F regulatory filings in the biotech sector for the first quarter.

BioCryst Provides Corporate Update And Reports First Quarter 2012 Financial Results

BioCryst Provides Corporate Update And Reports First Quarter 2012 Financial Results

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced financial results for the first quarter ended March 31, 2012.

BioCryst To Report First Quarter 2012 Financial Results On May 7, 2012

BioCryst To Report First Quarter 2012 Financial Results On May 7, 2012

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that its first quarter 2012 financial results will be released on Monday, May 7, 2012.

BioCryst To Present At Two Upcoming Investor Conferences

BioCryst To Present At Two Upcoming Investor Conferences

BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) today announced that executives from BioCryst are scheduled to present and provide a corporate summary and update regarding the Company’s clinical programs at the...

Biotech Stock Mailbag: Vivus, Chelsea, BioCryst

Biotech Stock Mailbag: Vivus, Chelsea, BioCryst

Biotech columnist Adam Feuerstein answers readers' questions about health-care companies.

BioCryst Reports Fourth Quarter And Full Year 2011 Financial Results

BioCryst Reports Fourth Quarter And Full Year 2011 Financial Results

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced financial results for the fourth quarter and full year ended December 31, 2011.

BioCryst Announces Promising Results From Preclinical Studies Of BCX5191 For Hepatitis C

BioCryst Announces Promising Results From Preclinical Studies Of BCX5191 For Hepatitis C

BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) today announced favorable preclinical results for BCX5191, a novel adenine nucleoside analog targeting viral RNA polymerase for the potential treatment of hepatitis ...

BioCryst To Announce Fourth Quarter And Full Year 2011 Financial Results On February 16, 2012

BioCryst To Announce Fourth Quarter And Full Year 2011 Financial Results On February 16, 2012

BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) today announced that its fourth quarter and full year 2011 financial results will be released on Thursday, February 16, 2012.

Nancy Hutson Appointed To BioCryst’s Board Of Directors

Nancy Hutson Appointed To BioCryst’s Board Of Directors

BioCryst Pharmaceuticals, Inc., (NASDAQ:BCRX) today announced that Nancy J.

BioCryst Announces Positive Results From Its Ongoing BCX4208 Phase 2B Study In Patients With Gout

BioCryst Announces Positive Results From Its Ongoing BCX4208 Phase 2B Study In Patients With Gout

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced long-term results from the extension phase of its randomized Phase 2b study of BCX4208 added to allopurinol in patients with gout who had failed to reach...

5 Under-$10 Stocks Set to Soar

5 Under-$10 Stocks Set to Soar

These volatile stocks could pay off big in the near term.

BioCryst Pharmaceuticals Presents New BCX4208 Gout Data At The 2011 ACR/ARHP Annual Scientific Meeting

BioCryst Pharmaceuticals Presents New BCX4208 Gout Data At The 2011 ACR/ARHP Annual Scientific Meeting

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) presents new results today from its Phase 2b randomized, double-blind, dose-response study of BCX4208 in patients with gout who have failed to reach the clinically...

TheStreet Quant Rating: D- (Sell)